• FDA grants fast track designation to GEN-1 for advanced ovarian cancer

    3 days ago - By Healio

    The FDA granted fast track designation to GEN-1 for treatment of advanced ovarian cancer, according to the agent's manufacturer.
    GEN-1 is a DNA-mediated interleukin-12 immunotherapy.
    “Fast track designation is an important step in developing GEN-1 for advanced ovarian cancer,” Michael H. Tardugno, Celsion's chairman, president and CEO, said in a company-issued press release. “Presuming the encouraging data we are generating in early clinical studies continues, this designation supports an expedited path to market.... We are optimistic that GEN-1
    Read more ...